It has subsequently also been found to show antiviral activity against other single stranded RNA viruses such as corona virus (including MERS & SARS) Most importantly it has undergone success under many Clinical trails for the treatment of COVID-19 Disease
In late January 2020, Remdesivir was administered to the first US patient who was confirmed to be infected by SARS-CoV-2, in Snohomish County, Washington, for “compassionate use” after he progressed to pneumonia. While no broad conclusions were made based on the single treatment, the patient’s condition improved dramatically the next day The patient’s condition improve dramatically the next day
In 2013 to 2016 there was out break of Ebola in Western Africa during which gilead were asked to synthesis Remdesivir an Antiretroviral drug it was little effective towards ebola virus but worked to decrease of the outbreak
Remdesivir now can be used for COVID treatment it’s undergoing phase 3 of clinical trails to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March
Remdesivirn (RDV) is broad spectrum of antiviral activities against RNA viruses, including SARS-CoV and Middle East respiratory syndrome (MERS-CoV)
RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV
The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterparts of viral ATP. The selectivity value for RDV-TP suggests that it is more efficiently incorporated than ATP and two other nucleotide analogues
Once incorporated the inhibitor caused RNA synthesis arrest hence mechanism of action is delayed RNA chain termination these results help to explain the high potency of RDV against RNA viruses in cell-based assays.